Abstract
Evidence-based treatments are suggested for generalized anxiety disorder (GAD) and social anxiety disorder (SAD). Pharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs) and psychological treatment including cognitive-behavioral treatment (CBT) have been used as first-line treatments. However, many patients do not improve despite successful delivery of standard therapeutic interventions. The definition of treatment resistance is that standard treatments have been effectively delivered, but the results are ineffective. Overcoming treatment resistance requires reevaluation of the diagnosis and optimization of the treatments. Options for treatment-resistant GAD and SAD include augmentation with other antidepressants, atypical antipsychotics, benzodiazepines, and pregabalin. A partial NMDA agonist D-cycloserine was studied as a newer treatment option with exposure therapy in anxiety disorders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.
Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62:5–9.
Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Arch Gen Psychiatry. 1996;53(8):727–35.
Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59:54–60.
Ballenger JC, Davidson JR, Lecrubier Y, Nut DJ, Borkovec TD, Rickels K, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62:53–8.
Ballenger JC. Current treatment of the anxiety disorders in adults. Biol Psychiatry. 1999;46(11):1579–94.
Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015;17(2):191–206.
Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;153(10):1293–300.
Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11(9):805–14.
Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety. 2008;25(6):467–76.
Klumpp H, Keutmann MK, Fitzgerald DA, Shankman SA, Phan KL. Resting state amygdala-prefrontal connectivity predicts symptom change after cognitive behavioral therapy in generalized social anxiety disorder. Biol Mood Anxiety Disord. 2014;4(1):14.
Roy-Whitfield-Gabrieli S, Ghosh SS, Nieto-Castanon A, Saygin Z, Doehrmann O, Chai XJ, et al. Brain connectomics predict response to treatment in social anxiety disorder. Mol Psychiatry. 2016;21(5):680–5.
Byrne P, Cowley DS. Clinical approach to treatment-resistant panic disorder. In: Rosenbaum JF, Pollack MH, editors. Panic disorder and its treatment. New York: Marcel Dekker; 1998. p. 205–27.
Blanco C, Raza MS, Schneier FR, Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6(4):427–42.
Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs. 2003;12(4):663–72.
McDougle CJ, Barr LC, Goodman WK, Price LH. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology. 1999;24(1):1–24.
Nemeroff CB. New vistas in neuropeptide research in neuropsychiatry: focus on corticotrophin releasing factor. Neuropsychopharmacology. 1992;6:69–75.
Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev. 2003;23(5):559–605.
Holmes A, Heilig M, Rupniak NMJ, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci. 2003;24(11):580–8.
Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, et al. A double blind, placebo controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol. 1995;15(6):428–34.
Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62:37–42.
Krisanaprakornkit T, Sriraj W, Piyavhatkul N, Laopaiboon M. Meditation therapy for anxiety disorders. Cochrane Database Syst Rev. 2006;1:CD004998.
Hambrick JP, Weeks JW, Harb GC, Heimberg RG. Cognitive behavioral therapy for social anxiety disorder: supporting evidence and future directions. CNS Spectr. 2003;8(5):373–81.
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136–44.
Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration of intraamygdala infusions of D-cycloserine as assessed with fear potentiated startle in rats. J Neurosci. 2002;22(6):2343–51.
Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy for social anxiety disorder with D-Cycloserine. Arch Gen Psychiatry. 2006;63(3):298–304.
Canadian Psychiatric Association. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatr. 2006;51(8 Suppl 2):9S.
Rubio G, Lopez-Ibor JJ. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand. 2007;115(5):372–9.
Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry. 1996;168(3):308–13.
Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009;70(Suppl 2):32–8.
National Institute for Health and Clinical Excellence. Clinical guideline 22 (Amended). Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Available from at: http://www.nice.org.uk/CG022NICEguideline.
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567–96.
Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2008;9(4):248–312.
Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;4:CD005473.
Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321–5.
Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211–5.
Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67(3):381–5.
Patterson B, Van Ameringen M. Augmentation strategies for treatment-resistant anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2016;33(8):728–36.
Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86(1):99–104.
Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20(1):9–11.
Menza MA, Dobkin RD, Marin H. An open label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27(2):207–10.
Hoge EA, Worthington IIIJJ, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13(6):522–7.
Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25(5):497–9.
Schwartz TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002;36(2):53–7.
Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155(7):992–3.
Pollack M. Levetiracetam (Keppra) for anxiety. Curbside Consult. 2002;1(4):4.
Crane D. Tiagabine for the treatment of anxiety. Depress Anxiety. 2003;18(1):51–2.
Feltner DE, Pollack MH, Davidson JR, Stein MB, Fulterer R, Jefferson JW, et al. A placebo-controlled, double-blind study of pregabalin treatment of social phobia: outcome and predictors of response. J Eur Coll Neuropsychopharmacol. 2000;10:344–5.
Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022–30.
Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389–94.
Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240–9.
Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–40.
Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771–82.
Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371(9618):1115–25.
Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder. J Clin Psychiatry. 2006;67(9):1428–34.
Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002;63:152–5.
Pallanti S, Quercioli L. Resistant social anxiety disorder response to escitalopram. Clin Pract Epidemiol Ment Health. 2006;2(1):35.
Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull. 1995;31:767–71.
Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake non-responders. Int Clin Psychopharmacol. 1999;14(4):239–45.
Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry. 2003;57(4):313–5.
Simon NM, Korbly NB, Worthington JJ, Kinrys G, Pollack MH. Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients. CNS Spectr. 2002;7(9):655–7.
Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999;14(4):239–45.
Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365–8.
Shaywitz JE, Liebowitz MR. Antiepileptic treatment of anxiety disorders. Prim Psychiatry. 2003:51–6.
Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open-label trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004;65(12):1674–8.
Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003;18(3):169–72.
Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65(9):1219–22.
Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996;39(2):115–21.
Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(10):1725–7.
Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004;65(2):244–8.
Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67(3):286–95.
Blanco C, Okuda M, Markowitz JC, Liu SM, Grant BF, Hasin DS. The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010;71(12):1645–56.
Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544–9.
Mayo WE, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta analysis. Lancet Psychiatry. 2014;1(5):368–76.
Craske MG, Golinelli D, Stein MB, Roy-Byrne P, Bystritsky A, Sherbourne C. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary care setting? Psychol Med. 2005;35(11):1645–54.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Lee, K.S., Lee, S.H. (2019). Treatment Resistance in Anxiety Disorder: Generalized Anxiety Disorder and Social Anxiety Disorder. In: Kim, YK. (eds) Treatment Resistance in Psychiatry. Springer, Singapore. https://doi.org/10.1007/978-981-10-4358-1_14
Download citation
DOI: https://doi.org/10.1007/978-981-10-4358-1_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4357-4
Online ISBN: 978-981-10-4358-1
eBook Packages: MedicineMedicine (R0)